





OVERVIEW

Harvest One is a global cannabis company that develops and provides innovative health, wellness, and selfcare products to consumers and patients in regulated markets around the world. The Company's range of solutions is designed to enhance quality of life. Shareholders have significant exposure to the entire cannabis value chain through four wholly-owned subsidiaries: United Greeneries, a licensed producer; Satipharm, an innovative medical and nutraceutical division; Dream Water Global, a producer and distributor of natural sleep aids; and Delivra, an award winning topical company with proprietary transdermal technology, as well as a minority interest in Burb Cannabis, a BC-based cannabis retailer.

PORTFOLIO OF COMPANIES

				
<ul style="list-style-type: none"> Licensed Producer with diversified cultivation operations Developing premium recreational and medical cannabis products Supply agreements with 4 provinces and Shoppers Drug Mart 20,000 kg of indoor premium flower in 2020 Cannabis oils sales license from Health Canada. Product development underway for derivatives, including vape pens and topicals 	<ul style="list-style-type: none"> Specialized in cannabinoid-based health and wellness products CBD Gelpell® - clinically proven bioavailability to help solve dosing issues – 2 separate clinical trials (see below) Sold throughout Europe with major retailers including Holland & Barrett and launching in Canada 2020 Supply Agreement with GenCanna for GMP Certified CBD oil and finished products 	<ul style="list-style-type: none"> All natural, Health Canada & FDA approved sleep aid Currently sold in over 30,000 outlets including Shoppers, Walmart & Kroger First mover in the global, \$2.5 billion annual OTC sleep aid market CBD based formulations currently undergoing stability testing Innovative product line extensions including beauty & sports Global Partnership with Auston Matthews – NHL Superstar 	<ul style="list-style-type: none"> Market leader in natural, topical creams (LivRelief™) with broad product portfolio Unique proprietary transdermal delivery technology Significant distribution with major retailers throughout Canada Expected to launch in the United States by end of 2019 Cannabinoid based formulations already in place 	<ul style="list-style-type: none"> 20% ownership, maximum allowed by BC 2 cannabis retail stores in BC – Port Coquitlam Estimating 8-10 retail outlets in British Columbia Expansion planned throughout Canada and U.S. Robust brand merchandising strategy in place to support luxury brand

PRODUCT PORTFOLIO



SATIPHARM CLINICAL TRIALS: CBD GELPELL® CAPSULES



PHASE I *Bioavailability and Stability*

- Published in international medical journal, "Clinical Pharmacology in Drug Development", in 2017
- 67% bioavailability
- 30% higher bioavailability in direct comparison to GW Pharma – Sativex
- 8 hours of exposure in blood



PHASE II *Treatment of Pediatric Epilepsy*

- Published in peer review medical journal, "Epilepsy & Behavior", in 2019
- Median monthly seizure reduction - 82%
- 73% of patients rate very much improved
- 56% of patients had a reduction of at least 50% in total number of seizures

DISTRIBUTION / SUPPLY AGREEMENTS Multiple products in over 38,000 stores

     	        	         	        
--	---	--	---

FINANCIAL SNAPSHOT

Market Capitalization	\$103m
Issued Shares	215m
Warrants	35.9M (\$0.59 - \$2.30)
Options	20.3m
Cash	\$30m (As of March 31, 2019)
Debt	\$280k (As of March 31, 2019)
52 week Low/High	\$0.325 – \$1.15
Insider Holdings	Approx 26% (MMJ Holding)
Fiscal 2019 Q1-Q3	\$8.9m

As of September 20, 2019

INVESTMENT HIGHLIGHTS

- Experienced management team including Grant Froese, CEO is ex-COO of Loblaw Group of companies
- Global company with operations across the entire cannabis value chain (LP, medical/health, recreational, consumer, retail)
- Extensive distribution already in place across all divisions
- Significant product profile with cannabis and non-cannabis brands
- Established relationships through existing distribution agreements with major retailers throughout North America, EU, Australia, New Zealand, and Asia.
- Currently trading at less than a 2x multiple, based on fiscal 2020 analyst forecasts

FUTURE CATALYSTS

- Scaling up – three expansions coming online
- New derivative products launching October in Canada
- LivRelief™ entering the U.S. Market
- SatiPharm Gelpell® capsules (CBD and THC) launching in Canada
- Large scale extraction and manufacturing expansion
- New, CBD infused formulations of Dream Water and Delivra
- SatiPharm supply agreements with large European retailers
- Geographical expansion in Europe and LATAM.
- Burb expansion in Canada & U.S.

MANAGEMENT TEAM

Grant Froese – CEO	Nick Maltchev – CTO
Andrew Kain – COO	Andy Bayfield – CCO
Aaron Wong – CFO	Deb Milimaka Miles – CAO & CPO

ANALYST COVERAGE

Neal Gilmer – Haywood Securities - Target Price: \$1.20
Greg McLeish – Mackie Research - Target Price: \$2.00

This document includes forward-looking statements that by their very nature involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Such forward-looking statements are based on current expectations, estimates and projections about our industry, management beliefs and certain assumptions made by our management. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Unless required by law, we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise to reflect future events or circumstances or reflect the occurrence of unanticipated events.